Drospirenone: An antihypertensive in waiting

Hypertension

Volumn 48, Issue 2, 2006, Pages 205-206

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; ENALAPRIL; EPLERENONE; ETHINYLESTRADIOL; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; ATHLETE; BLOOD PRESSURE MONITORING; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG SAFETY; DRUG USE; EDITORIAL; HUMAN; HYPERKALEMIA; HYPERTENSION; LOW DRUG DOSE; ORAL CONTRACEPTION; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT OUTCOME; VASOMOTOR DISORDER;

AGE FACTORS; ANDROSTENES; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOPING IN SPORTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; FEMALE; HUMANS; HYPERTENSION; POSTMENOPAUSE; UNITED STATES;

EID: 33748181181     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000232180.72752.f8     Document Type: Editorial

References (10)

1. US Antidoping Agency-http://www.usantidoping.org. Accessed May 29, 2006.
2. Oelkers WH. Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric. 2005;3:19-27.
3. Preston RA, Alonso A, Panzitta D, Zhang P, Karara AH. Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens. 2002;15:816-822.
4. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens. 2005;18:797-804.
5. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 β-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112:1979-1984.
6. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17β-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48:246-253.
7. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Moll Cell Endocrinol. 2004;217:255-261.
8. Oelkers W, Berger V, Bolik A, Bahr V, Hazard B, Beier S, Elger W, Heithecker R. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab. 1991;73:837-842.
9. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816-1821.
10. Sica DA. Eplerenone: A new aldosterone receptor antagonist: Are the FDA's restrictions appropriate. J Clin Hypertens. 2002;4:441-445.